Recent Company News

• 02:01 PM ET May 11, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 4-May

• 12:39 AM ET May 08, 2026
  

  Lonza qualitative Q1 business update: strong performance across CDMO business (CHF 486.20, 0.00)

• 11:09 AM ET May 01, 2026
  

  US FTC grants antitrust clearance for Lone Star Funds' purchase of Lonza Group's Capsules & Health Ingredients business (CHF 479.20, 0.00)

• 07:57 AM ET Apr 21, 2026
  

  Simulations Plus announces funded research collaboration with Lonza Group and FDA to advance predictive frameworks for complex oral drug products ($14.97, 0.00)

• 12:34 AM ET Apr 01, 2026
  

  Lonza Group publishes 2025 Sustainability Report (CHF 504.80, 0.00)

• 06:05 AM ET Mar 26, 2026
  

  Kodiak Sciences announces topline results in the GLOW2 Phase 3 superiority study of Zenkuda ($22.75, 0.00)

• 08:33 AM ET Mar 23, 2026
  

  Vaxcyte completes enrollment of OPUS-1 and OPUS-2 phase 3 trials evaluating VAX-31 for the prevention of invasive pneumococcal disease and pneumonia in adults ($54.72, 0.00)

• 04:55 AM ET Mar 23, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (316 total)

• 07:51 PM ET Mar 18, 2026
  

  Vaxcyte VAX-31 Phase 1/2 adult data results published in The Lancet Infectious Diseases ($54.28, 0.00)

• 02:09 PM ET Mar 16, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 9-Mar